glp 1 dementia GLP-1 Medications Associated with Reduced Likelihood of Compared to Other Diabetic Meds GLP-1 receptor agonists effect on

In 2025 , Novo Nordisk announced positive Phase 3 ESSENCE trial results evaluating semaglutide for early Alzheimers disease, demonstrating potential neuroprotective effects and opening new therapeutic opportunities

S5 show that GLP-1RA were associated with lower risks as compared with placebo (16% lower risk), DPP-4 inhibitors (15% lower risk) and SGLT-2 inhibitors (10% lower risk), but the difference was statistically significant as compared with placebo only

Start searching today to find providers offering FDA-approved options

Weeks 17 onward: 12mg weekly maintenance for those in the highest arm

For studies with measurements of plasma insulin and glucagon concentrations, plasma was collected by tail vein bleeding at timepoints 0, 60, 120 and 240 min

E., Tobin A